New Content  edit
Get The App!

Loading the player...
Outcomes in Patients with Myelofibrosis: Pacritinib vs. BAT in the Phase III Persist-1 Trial
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
At ASH 2015, Dr. Alessandro Vannucci from the University of Florence discusses his abstract titled "Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib vs. Best Available Therapy (BAT) in the Phase III Persist-1 Trial."